The Evolving Role of Antiplatelet Therapy in Neurovascular Procedures
Neurovascular procedures represent a critical frontier in modern medicine, addressing complex conditions affecting the brain's blood vessels, such as aneurysms, arteriovenous malformations, and stenoses. While these interventions offer life-saving and life-altering benefits, they inherently carry risks, particularly those related to thrombosis and hemorrhage. To mitigate thrombotic complications, **antiplatelet therapy** plays an indispensable role. This article delves into the crucial function of antiplatelet agents in various neurovascular procedures, examining common medications, associated challenges, and the evolving strategies aimed at optimizing patient outcomes.
Understanding Antiplatelet Therapy: Mechanisms and Modalities
Antiplatelet agents are a class of medications designed to prevent the formation of blood clots by inhibiting platelet aggregation. The primary goal in neurovascular interventions is to maintain vessel patency and prevent ischemic events without unduly increasing the risk of bleeding. Key antiplatelet agents commonly employed include:
- **Aspirin:** This agent irreversibly inhibits cyclooxygenase-1 (COX-1), thereby reducing the production of thromboxane A2, a potent vasoconstrictor and platelet activator. Low-dose aspirin selectively inhibits COX-1, minimizing systemic side effects [1].
- **Clopidogrel:** A prodrug, clopidogrel requires metabolic activation by cytochrome P450 (CYP) enzymes, primarily CYP2C19, to its active form. This active metabolite then irreversibly binds to the P2Y12 receptor on platelets, preventing ADP-induced platelet activation and aggregation [2].
- **Ticagrelor and Prasugrel:** These are newer, more potent P2Y12 inhibitors. Ticagrelor is a reversibly binding agent, while prasugrel is an irreversible prodrug with more consistent and rapid platelet inhibition compared to clopidogrel [2].
Antiplatelet therapy is often administered as either **Single Antiplatelet Therapy (SAPT)** or **Dual Antiplatelet Therapy (DAPT)**. DAPT, typically involving aspirin and a P2Y12 inhibitor, is a cornerstone in many neurovascular procedures, particularly those involving stent placement, to prevent in-stent thrombosis. However, the choice between SAPT and DAPT, and the specific agents used, is highly individualized and depends on the procedure, patient comorbidities, and the balance between ischemic and hemorrhagic risks.
One significant challenge in antiplatelet therapy is **antiplatelet resistance**, where patients exhibit a suboptimal response to standard antiplatelet regimens. This can be due to genetic polymorphisms (e.g., in CYP2C19 affecting clopidogrel metabolism) or drug-drug interactions [2]. This variability underscores the need for personalized approaches to therapy.
Antiplatelet Strategies in Specific Neurovascular Procedures
The application of antiplatelet therapy varies considerably across different neurovascular interventions:
Intracranial Stenting
For procedures involving intracranial stenting, such as for intracranial atherosclerotic disease (ICAD) or stent-assisted coiling of aneurysms, DAPT is generally recommended. Patients with symptomatic ICAD, for instance, should continue DAPT following neurointerventional treatment for secondary stroke prevention [1]. The duration of DAPT typically extends for at least 3 months post-procedure, with consideration for reversion to SAPT based on the individual patient's risk profile [1]. Pre-procedural management often involves initiating DAPT several days prior to the intervention to ensure adequate platelet inhibition.
Aneurysm Coiling
In the context of aneurysm coiling, particularly stent-assisted coiling, DAPT is crucial to prevent thromboembolic complications associated with the stent. However, managing antiplatelet therapy in ruptured aneurysms presents a unique challenge due to the heightened risk of hemorrhage. Recent advancements include the use of surface-modified flow diverter stents (FDSs) in conjunction with SAPT (e.g., ticagrelor or prasugrel) and periprocedural bridging with intravenous agents like tirofiban. This approach has shown promising results in ruptured blood blister-like aneurysms, achieving high occlusion rates with minimal thromboembolic and hemorrhagic complications [3]. For patients with unruptured brain arteriovenous malformations, existing antiplatelet or anticoagulant management for other conditions typically does not require alteration [1].
Carotid Artery Stenting (CAS)
Patients undergoing CAS are generally recommended to receive DAPT both before and for at least 3 months following the procedure [1]. In emergent situations, such as CAS during large vessel occlusion ischemic stroke treatment, a loading dose of intravenous or oral glycoprotein IIb/IIIa or P2Y12 inhibitor, followed by maintenance dosing, may be administered to prevent stent thrombosis [1].
Cerebral Venous Sinus Thrombosis
For cerebral venous sinus thrombosis, anticoagulation with heparin is the front-line therapy. Endovascular therapy may be considered in cases of clinical deterioration despite medical management [1].
The Role of Platelet Function Testing and Personalized Medicine
Given the variability in individual responses to antiplatelet medications, **platelet function testing (PFT)** has emerged as a tool to assess the effectiveness of therapy and guide personalized treatment strategies. While PFT can be useful in guiding local practice, the optimal assay, thresholds, and agents remain subjects of ongoing debate due to interpatient variability [2]. Various assays exist, but their clinical utility and standardization are still under investigation. The ultimate goal is to tailor antiplatelet regimens to individual patients, balancing the risk of thrombosis against the risk of hemorrhage, thereby moving towards a more personalized medicine approach.
Challenges and Future Directions
The management of antiplatelet therapy in neurovascular procedures is a delicate balance between preventing ischemic events and avoiding hemorrhagic complications. The evidence base, while growing, is often derived from studies in cardiac and peripheral vascular diseases, necessitating nuanced application in the neurointerventional setting. There is a clear need for more prospective, randomized studies specifically designed for neurointerventional patient populations to strengthen the data supporting current recommendations [1, 2]. Future directions include the development of novel antiplatelet agents with improved efficacy and safety profiles, as well as advanced diagnostic tools for more precise PFT, paving the way for truly individualized antiplatelet strategies.
Conclusion
Antiplatelet therapy is an indispensable component of neurovascular care, playing a pivotal role in preventing thrombotic complications associated with various interventional procedures. The landscape of antiplatelet management is continuously evolving, with ongoing research into new agents, personalized strategies, and refined guidelines. While significant progress has been made, the complexity of balancing ischemic and hemorrhagic risks necessitates a meticulous, individualized approach to patient care, supported by robust clinical evidence and continuous advancements in the field.
References
[1] Schirmer, C. M., Bulsara, K. R., Al-Mufti, F., et al. (2023). Antiplatelets and antithrombotics in neurointerventional procedures: Guideline update. *Journal of NeuroInterventional Surgery*, *15*(11), 1155. [https://jnis.bmj.com/content/15/11/1155](https://jnis.bmj.com/content/15/11/1155)
[2] Fukuda, K. A., Beaman, C., & Szeder, V. (2024). Antiplatelet Therapy and Platelet Activity Testing for Neurointerventional Procedures. *Stroke: Vascular and Interventional Neurology*, *5*(1). [https://www.ahajournals.org/doi/10.1161/SVIN.124.001376](https://www.ahajournals.org/doi/10.1161/SVIN.124.001376)
[3] Chen, C. C., Chen, C. T., Yeap, M. C., et al. (2025). Single antiplatelet therapy and tirofiban bridged with surface modified flow diverters for ruptured blood blister-like aneurysms: single center experience and systematic review. *Journal of NeuroInterventional Surgery*. [https://jnis.bmj.com/content/early/2025/08/13/jnis-2025-023832](https://jnis.bmj.com/content/early/2025/08/13/jnis-2025-023832)